Mike Norris
Nessuna posizione attualmente
Profilo
Mike Norris is Vice President of Corporate Development for CardioVascular BioTherapeutics, Inc. Previously, he was Vice President of Strategy, Enablement and Measurement for Digitas, Inc. Mr. Norris worked with Xerox, the Associates, American Century, JC Penny Insurance and Williams-Sonoma.
Prior to joining Digitas, he was a Senior Manager of KPMG Consulting and Chief Executive Officer of MedQuest.
Mr. Norris received a BS and an MS in Electrical Engineering from the University of Illinois, Urbana, and an MBA from the University of St. Thomas, Houston, Texas.
Precedenti posizioni note di Mike Norris
| Società | Posizione | Fine |
|---|---|---|
Venturis Therapeutics, Inc.
 Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Corporate Officer/Principal | - |
Formazione di Mike Norris
| University of Illinois | Graduate Degree |
| University of St. Thomas (Texas) | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
- Borsa valori
- Insiders
- Mike Norris
